1. Patients with decompensated chronic diseases (high blood pressure, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, asthma, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias, Addison's disease) 2. Patients with immunosuppression due to cancer, HIV or long-term treatment with immunosuppressants 3. Patients with chronic kidney failure4. Patients with digestive autoimmune diseases (Crohn's disease, ulcerative colitis, among others) or thyroid 5. Pregnant or breastfeeding 6. Patients with treatments that deplete sodium or maintain a sodium restrictive diet 7. Patients with psychiatric illnesses or mental disabilities that prevent them from expressing their willingness to participate in the study or make its evaluation difficult 8. Patients hypersensitive to lithium 9. Lactose intolerant patients 10. Woman of childbearing age who does not use contraception and does not undertake to use it for at least one month after the end of the study treatment. 11. Patient participating in another clinical trial at the time of selection

1. Patients with decompensated chronic diseases (high blood pressure, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, asthma, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias, Addison's disease) 2. Patients with immunosuppression due to cancer, HIV or long-term treatment with immunosuppressants 3. Patients with chronic kidney failure4. Patients with digestive autoimmune diseases (Crohn's disease, ulcerative colitis, among others) or thyroid 5. Pregnant or breastfeeding 6. Patients with treatments that deplete sodium or maintain a sodium restrictive diet 7. Patients with psychiatric illnesses or mental disabilities that prevent them from expressing their willingness to participate in the study or make its evaluation difficult 8. Patients hypersensitive to lithium 9. Lactose intolerant patients 10. Woman of childbearing age who does not use contraception and does not undertake to use it for at least one month after the end of the study treatment. 11. Patient participating in another clinical trial at the time of selection